DAY 1 (May 26)
Conference registration day and welcome dinner
(Hotel check-in, networking and informal discussions)
CONFERENCE SESSIONS
DAY 2 (May 27)
|
8:00 AM |
|
Breakfast |
|
|
|
|
|
|
|
|
|
8:50 AM |
|
Welcome and Opening Remarks John Lambris (on behalf of the Organizing Committee) |
|
|
|
|
|
|||
|
SESSION I |
Structural insights and mechanisms of activation, regulation and crosstalk Chairs: Anna Blom and Brian Geisbrecht |
|
||
|
9:00 AM |
1 |
Structural insight on the function of properdin in the alternative pathway Gregers Andersen Aarhus University, Denmark |
|
|
|
9:20 AM |
2 |
A review of the double inhibition of complement and TLRs - from the origin on the bench through animal studies and possible clinical applications Tom E. Mollnes Oslo University, Norway |
|
|
|
9:40 AM |
3 |
FcγR-mediated Trogocytosis 2.0: Revisiting History gives rise to a Unifying Hypothesis Ronald Taylor University of Virginia, USA |
|
|
|
10:00 AM |
4 |
Cytosolic C3 in cellular homeostasis and defence Benjamin King Lund University, Sweden |
|
|
|
10:20 AM |
5 |
Granzyme K activates a new complement pathway Carlos Donado, Helena Jonsson and Erin Theisen Harvard Medical School, USA |
|
|
|
10:35 AM |
|
Coffee Break and Poster Viewing |
|
|
|
|
|
|
|
|
|
SESSION II |
Therapeutic development: novel complement inhibitors Chairs: Monica Olcina and Daniel Ricklin |
|
||
|
11:15 AM |
6 |
The dawn of clinical C3 inhibition: the story, its milestones and what lies ahead John D. Lambris Perelman School of Medicine, University of Pennsylvania, USA |
|
|
|
11:35 AM |
7 |
Mechanistic and therapeutic aspects in complement-driven periodontal disease George Hajishengallis, Hatice Hasturk, Dimitrios Mastellos, Despina Yancopoulou, and John Lambris Penn Dental Medicine, University of Pennsylvania, USA |
|
|
|
11:55 AM |
8 |
A new treatment paradigm for Paroxysmal Nocturnal Hemoglobinuria: the era of proximal complement inhibitors Antonio M. Risitano, Camilla Frieri, Luana Marano, Despina Yancopoulou, Dimitrios Mastellos, John D. Lambris University of Napoli Federico II, Italy |
|
|
|
12:15 AM |
9 |
Drug and druggability: A new era in complement-targeted therapeutics and novel approaches off the conventional path Daniel Ricklin, Said Rabbani, Oliver Schwardt, Rachel Hevey, Ekaterina Umnyakova, Peter Rüthemann, Clément Bechtler, Kevin Widmer, Aleksandra Blagojevic, Stephanie Vogt, Jannes Felsch, Murielle Golomingi, Christina Lamers, Richard Pouw, Martin Smiesko, Markus Lill, Verena Schroeder, Christoph Schmidt and John Lambris University of Basel, Switzerland |
|
|
|
12:35 PM |
10 |
Continued investigations of modified DNA aptamers as inhibitors of complement proteins and their complexes Brian Geisbrecht, Huiquan Duan, and Ying Zhang Kansas State University, USA |
|
|
|
12:55 PM |
11 |
An Oral C5aR receptor antagonist blocks disease in the C3 gain-of-function mouse model of aHUS Kate Smith-Jackson, Isabel Pappworth, Beth Gibson, Thomas Hoyler, Marianne Martinic, Mark Murphy , and Kevin Marchbank Newcastle University, UK |
|
|
|
13:10 PM |
12 |
Complement inhibition prevents paranodal loop injury in an anti-GM1 antibody-mediated paranodal demyelinating mouse model Inge Van de Walle, Clare Campbell, Rhona McGonigal, Jennifer Barrie, Jolien Delaere, Laura Bracke, Madelaine Cunningham, Denggao Yao, Tim Delahaye, and Hugh Willison Research and Development, Argenx BV |
|
|
|
13:25 PM |
13 |
Probing C3 modulation in the intracellular space: Cellular internalization of compstatin-based C3 inhibitors and its functional implications Dimitrios Mastellos, Rebecca Lee, Merita Rumano, George Hajishengallis, Despina Yancopoulou and John D. Lambris National Center for Scientific Research ‘Demokritos’ |
|
|
|
13:40 PM |
|
Lunch and Informal Discussions |
|
|
|
|
|
|||
|
|
|
|||
|
7:30 PM |
|
Dinner and Informal Discussions |
|
|
|
|
|
|
|
|
|
DAY 3
|
|
(May 28) |
|
|
|
|
|
|
||
|
SESSION III |
Targeting complement in neurological diseases Chairs: Andrea Tenner and Wioleta Zelek |
|
||
|
9:00 AM |
14 |
Complement in neuroinflammatory and neurodegenerative diseases Paul Morgan Cardiff University, UK |
|
|
|
9:20 AM |
15 |
Progressive neurological injury, early neurological deterioration and microvascular dysfunction following endovascular thrombectomy for larger vessel stroke: a target for anti-complement therapeutics E. Sander Connolly Columbia University, USA |
|
|
|
9:40 AM |
16 |
A detrimental role for complement C5aR1 activation in Huntington’ s disease John Lee University of Queensland, Australia |
|
|
|
10:00 AM |
17 |
New shot on goal: Targeting inflammation and synapse loss to suppress Alzheimer’s disease Andrea Tenner, Nicole Schartz, Heidi Liang, Shu-Hui Chu, Angela Gomez-Arboledas, and Ali Mortazavi University of California at Irvine, USA |
|
|
|
10:20 AM |
18 |
Generation and characterization of C3 inducible conditional KO Alzheimer’s-like mice Brijendra Singh, Andre Batista, Maren Schroeder, Khyrul Khan, Emma Spooner, Takashi Saito, Hiroki Sasaguri, Takaomi Saido, Michael Carroll, and Cynthia Lemere Harvard Medical School, USA |
|
|
|
10:40 AM |
19 |
The therapeutic potential of C3aR agonists in the post-acute phase after stroke Marcela Pekna University of Gothenburg, Sweden |
|
|
|
11:00 AM |
20 |
The role of the terminal pathway in driving pathology in dementia Wioleta Zelek, Ryan Bevan, and Paul Morgan Cardiff University, UK |
|
|
|
11:20 AM |
21 |
Aberrant protein S-nitrosylation of C3 activates phagocytosis of neuronal synapses by microglia in Alzheimer's disease Hongmei Yang, Chang-ki Oh, Haitham Amal, John S. Wishnok, Sarah Lewis, Emily Schahrer, Dorit Trudler, Tomohiro Nakamura, Steven R. Tannenbaum, Stuart A. Lipton Scripps Research Institute, USA |
|
|
|
11:40 AM |
|
Coffee Break and Poster Viewing |
|
|
|
|
|
|||
|
SESSION IV |
Complement in thromboinflammation Chairs: Lubka Roumenina and Mikkel-Ole Skjoedt |
|
||
|
12:15 PM |
22 |
The complement regulator MAP-1 interacts with activated FXII and attenuates the coagulation system Mikkel-Ole Skjoedt University of Copenhagen, Denmark |
|
|
|
12:35 PM |
23 |
An alternative binding and activation mechanism of native C3 induced by contact with biosurfaces without involvement of the thioester Bo Nilsson, Anna Adler, Osama Hamad, Claudia Dührkop, Roland Ebert, Yuji Teramura, Kristina Ekdahl, and Karin Fromell Uppsala University, Sweden |
|
|
|
12:55 AM |
24 |
Escherichia coli-induced platelet aggregation in human whole blood is inhibited by compstatin and is C3b-dependent Anne Landsem, Åse Emblem, Corinna Lau, Dorte Christiansen, Alexandra Gerogianni, Bård Karlsen, Tom Mollnes, Per Nilsson, and Ole Brekke University of Tromsø, Norway |
|
|
|
13:10 PM |
25 |
A MaGical cASe: a story on the cell-specific effects of C3-mediated neurodegeneration Maria-Tzousi Papavergi, Brijendra Singh, Andre Batista, Praveen Bathini, Emma Spooner, Shaomin Li, and Cynthia Lemere Harvard Medical School, USA |
|
|
|
13:25 PM |
Lunch and Informal Discussions |
|
||
|
|
|
|
|
|
|
7:30 PM |
Dinner and Informal Discussions |
|
||
|
|
|
|
||
|
DAY 4 |
|
(May 29) |
|
|
|
|
|
|
|
|
|
SESSION V |
Targeting Complement in cancer and kidney diseases Chairs: Sophie Chauvet and Ruben Pio |
|
||
|
9:00 AM |
26 |
The C5a/C5aR1 axis in tumor-associated myeloid cells Ruben Pio University of Navarra, Spain |
|
|
|
9:20 AM |
27 |
Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy Carsten Krieg, Lukas Weber, Bruno Fosso, Marinella Marzano, Monica Olcina, Enric Domingo, Mark Robinson, and Silvia Guglietta Medical University of South Carolina, USA |
|
|
|
9:35 AM |
28 |
Understanding the role of C5aR1 in tumours with immunosuppressive microenvironments Monica Olcina Oxford University, UK |
|
|
|
9:55 AM |
29 |
Intracellular Functions of Complement proteins in health and in Diseases affecting the Kidney Lubka Roumenina Cordeliers Research Center, Sorbonne University, France |
|
|
|
10:15 AM |
30 |
In situ Complementomics in kidney diseases and cancer Idris Boudhabhay, Margot Revel, Marie Sophie Meuleman, Amine Majdi, Antonin Bourdin, Sophie Chauvet, and Lubka Roumenina Cordeliers Research Center, INSERM, France |
|
|
|
10:30 AM |
31 |
Impact of C3 and soluble C5b-9 levels on renal outcomes in C3 glomerulopathy : results from a national-wide retrospective cohort Sophie Chauvet Department of Nephrology, APHP, France |
|
|
|
10:45 AM |
32 |
Evaluation of minimal factor H therapy administered to kidneys during ex vivo normothermic perfusion as a treatment to improve ischaemia reperfusion injury Chloe Connelly, Beth Gibson, Balaji Mahendran, Samuel Tingle, Lucy Bates, Madison Cooper, Emily Thompson, Colin Wilson, Neil Sheerin, and Kevin Marchbank Newcastle University, UK |
|
|
|
11:00 AM |
|
Coffee Break and Poster Viewing |
|
|
|
|
|
|
|
|
|
SESSION VI |
Complement in ocular inflammation and infectious diseases Chairs: Cecilia Garlanda and Benjamin King |
|
||
|
11:40 AM |
33 |
Age-related Macular Degeneration: a Tale of Two RPE-centric Diseases, of Which Only One is Complement-driven Gregory Hageman, Brandi Williams, Jin Liu, Robert Anstadt, Nathan Seager, Julie Thomas, Jill Hageman, Steffen Schmitz-Valckenberg, Monika Fleckenstein, Karen Curtin, Chris Pappas, Moussa Zouache, and Burt Richards University of Utah, USA |
|
|
|
12:00 PM |
34 |
Bacterial evasion strategy as basis for novel antimicrobial treatment Anna Blom Lund University, Sweden |
|
|
|
12:20 PM |
35 |
Humoral Innate Immunity and Acute Phase Proteins in COVID-19 Cecilia Garlanda Humanitas University, Italy |
|
|
|
12:40 PM |
36 |
The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2 Matteo Stravalaci, Isabel Pagani, Hang Zhong, Marina Sironi, Simone Bondesan, Federica Barzaghi, Paola Carrera, Francesca Izzo, Elena Zoia, Elisa Vicenzi, Barbara Bottazzi, Rosanna Asselta, Giorgio Casari, Alessandro Aiuti, Alberto Mantovani, and Cecilia Garlanda Humanitas University, Italy |
|
|
|
12:55 PM |
|
(15 min) ‘Flash’ poster session A |
|
|
|
13:10 PM |
Lunch and Informal Discussions |
|
||
|
|
|
|||
|
15:00 PM |
|
(GUIDED CITY TOUR) |
|
|
|
7:30 PM |
Dinner and Informal Discussions |
|
||
|
|
|
|
||
|
DAY 5 |
(May 30) |
|
||
|
SESSION VII |
Mechanisms and therapeutic targets in immune-mediated and inflammatory diseases Chairs: Silvia Guglietta and Carl Atkinson |
|
||
|
9:00 AM |
37 |
Modulation of lung injury by tissue-specific C3 expression Hrishikesh Kulkarni Washington University School of Medicine, St Louis, USA |
|
|
|
9:20 AM |
38 |
RNA Profiling and protein expression studies in the synovium of both rheumatoid arthritis and post-traumatic injury identify causal pathogenic mechanisms for complement activation in both diseases V Michael Holers and Nirmal Banda University of Colorado, Denver, USA |
|
|
|
9:40 AM |
39 |
Compstatins abolish pathogenic fibroblast function associated with inflammatory tissue priming Jasna Friscic, Xi Chen, John Lambris, and Markus Hoffmann University of Lübeck, Germany |
|
|
|
10:00 AM |
40 |
C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection Jigar Desai, Claudia Kemper, Ben Afzali, Jörg Köhl, and Michail Lionakis Fungal Pathogenesis Section, NIAID, NIH |
|
|
|
10:20 AM |
41 |
Both liver-derived and intracellular complement modulate hematopoietic stem/progenitor cell metabolism and stress response Mariusz Ratajczak University of Louisville, USA |
|
|
|
10:40 AM |
42 |
TBD Carl Atkinson Medical University of South Carolina, USA |
|
|
|
11:00 AM |
|
‘Flash’ poster session B |
|
|
|
11:15 AM |
|
Coffee Break and Poster Viewing |
|
|
|
|
|
|
|
|
|
SESSION VIII |
Disease biomarkers and complement diagnostics Chairs: Veronique Fremeaux-Bacchi and Zoltan Prohászka |
|
||
|
11:55 AM |
43 |
Stratification of patients with complement mediated diseases for complement targeted therapies: the perspective from the diagnostic complement laboratory Ashley Frazer-Abel, Michael Kirschfink and Zoltan Prohászka Semmelweis University, Hungary |
|
|
|
12:15 PM |
44 |
Comprehensive genetic evaluation for the diagnosis of complement alternative pathway-mediated kidney diseases Veronique Fremeaux-Bacchi Assistance Publique - Hospitaux de Paris, France |
|
|
|
12:35 PM |
45 |
Ex vivo complement activation on endothelial cells: set up of a new functional tool to explore complement dysregulation Anna Duval, Marie-Sophie Meuleman, Lubka Roumenina, Sophie Caillard, and Veronique Fremeaux-Bacchi Cordeliers Research Center, INSERM, France |
|
|
|
12:50 PM |
46 |
Identification of genes involved in the protective response of C3aR in amyotrophic lateral sclerosis pathology Jenny Fung, John Lee and Trent Woodruff University of Queensland, Australia |
|
|
|
13:05 PM |
47 |
Distinct cell-bound complement activation products associate with disease activity and immune transcriptional programs in systemic lupus erythematosus Gabriel Arguelles, Lynne Mitchell, Dennis Hourcade, John Atkinson, Elisha Roberson and Alfred Kim Washington University School of Medicine, USA |
|
|
|
|
|
|
|
|
|
13:20 PM |
|
Closing remarks Lubka Roumenina, Dimitrios Mastellos (On behalf of the organizing committee) |
|
|
|
|
|
|
|
|
|
13:30 PM |
|
Lunch and Informal Discussions |
|
|
|
|
|
|
|
|
|
8:00 PM |
Farewell dinner |
|
||
|
|
|
|
||
|
DAY 6 |
(May 31) |
|||
|
|
Departure day |
|||
POSTER session
The conference will include 1-2 live poster sessions where registered presenters will be able to give a 3-min ‘flash’ poster talk highlighting the main findings of their study.
1. Determining the activity of the alternative and lectin path of the complement system in the fibrinogen coagulation test to predict of the severity of the COVID-19. Batozhab Shoibonov
2. Complement Factor B activation test specificity in the rapid test format: generation and characterization of new Ba neo-epitope specific monoclonal antibodies. Mollie O'Neill, George Adegbuyi , Dan Mills, Michelle Elvington, Niamh O'Luanaigh, and Martin Schmidt
3. Involvement of PTX3 and MBL in the clearance of SARS-CoV-2 infected lung airway epithelial cells. Hang Zhong, Matteo Stravalaci, Isabel Pagani, Niloufar Kavian-Tessler, Barbara Bottazzi, Poli Guido, Elisa Vicenzi, and Cecilia Garlanda
4. Complement activation as a biomarker and pathogenic factor in rhabdomyolysis-induced acute kidney injury. Idris Boudhabhay, Anne Grunenwald, and Lubka Roumenina
5. Glycan structure optimization of moss produced human complement factor H markedly improves pharmacokinetic and pharmacodynamics properties in vivo. Todor Tschongov, Swagata Konwar, Paulina Dabrowska-Schlepp, Christian Sievert, Andreas Busch, Jens Panse, and Karsten Häffner.
6. Correlation of systemic and in situ biomarkers of complement activation with histopathological features and prognosis in C3 glomerulopathy. Marie-Sophie Meuleman, Anna Duval, Veronique Fremeaux-Bacchi, Jean-Paul Duong, and Sophie Chauvet
7. C1-INH complexes as markers for classical and lectin pathway activation. Lisa Hurler, Erika Kajdácsi, Erik Toonen, Bregje van Bree, György Sinkovits, László Cervenak, Reinhard Würzner, and Zoltan Prohászka
8. A Novel Functional Properdin Assay Studying the Positive AP Regulator and Complement Amplification Loop. Samuel Butler, Viktoria Kozma, Cecilia Månsson, Camilla Nilsson, Ali Qamar, Michael Schwenkert, and Therese Segerstein
9. Aspergillus fumigatus induces tumor necrosis factor release in a complement C3-dependent manner in lepirudin anticoagulated human whole blood. Beatrice Fageräng, Maximilian Götz, Per Nilsson, Tom Mollnes, and Peter Garred
10. Rapid complement inhibition with the C5 inhibitor crovalimab: timing analysis using animal model and COMPOSER trial data. Niamh Gould
11. The immune cell landscape of the injured brain and its relation to the complement system in traumatic brain injury. Amer Toutonji, Carsten Krieg, Davis Borucki, Stephen Tomlinson, and Silvia Guglietta
12. Immunopathology of Terminal Complement Activation and Complement C5 Blockade Creating a Pro-survival and Organ-protective Phenotype in Trauma. Zhansheng Yang, Miles Nunn, Tuan Le, Milomir Simovic, Peter Edsall, Bin Liu, Johnny Barr, Brian Lund, Crystal Hill-Pryor, Anthony Pusateri, Leopoldo Cancio, and Yansong Li
13. Differential proteins including complement factor H in the aqueous humor from patients with dry age-related macular degeneration (AMD). Hyewon Chung
14. Cerebrospinal fluid proteomics in recent-onset Narcolepsy type 1 reveals activation of the complement system. Ikram Ayoub